Lower toxicity with targeted anticancer agents in phase I trials

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2012年 / 1416卷 / 1期
关键词：
Independent Predictor; Component Variable; National Cancer Institute; Anticancer Agent; Advanced Cancer;
D O I：
10.2165/00128415-201214160-00005
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3 / 3
相关论文
共 50 条
  • [21] Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: A review of the literature
    Le Tourneau, Christophe
    Razak, Albiruni R. A.
    Gan, Hui K.
    Pop, Simona
    Dieras, Veronique
    Tresca, Patricia
    Paoletti, Xavier
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (10) : 1468 - 1475
  • [22] Palliative care: A supportive adjunct to pediatric phase I clinical trials for anticancer agents?
    Ulrich, CM
    Grady, C
    Wendler, D
    PEDIATRICS, 2004, 114 (03) : 852 - 855
  • [23] Phase I and II evaluation of novel anticancer agents: Are response and toxicity the right endpoints?
    Eisenhauer, EA
    ONKOLOGIE, 2000, 23 : 2 - 6
  • [24] Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical Trials
    Seruga, Bostjan
    Sterling, Lynn
    Wang, Lisa
    Tannock, Ian F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) : 174 - 185
  • [25] SEAMLESS PHASE I/II ADAPTIVE DESIGN FOR ONCOLOGY TRIALS OF MOLECULARLY TARGETED AGENTS
    Wages, Nolan A.
    Tait, Christopher
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2015, 25 (05) : 903 - 920
  • [26] Phase III Trials of Targeted Anticancer Therapies: Redesigning the Concept
    Ocana, Alberto
    Amir, Eitan
    Vera-Badillo, Francisco
    Seruga, Bostjan
    Tannock, Ian F.
    CLINICAL CANCER RESEARCH, 2013, 19 (18) : 4931 - 4940
  • [27] A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies
    Cohen, Julia W.
    Akshintala, Srivandana
    Kane, Eli
    Gnanapragasam, Helen
    Widemann, Brigitte C.
    Steinberg, Seth M.
    Shah, Nirali N.
    ONCOLOGIST, 2020, 25 (06): : 532 - 540
  • [28] An adaptive design for the identification of the optimal dose using joint modelling of efficacy and toxicity in phase I/II clinical trials of molecularly targeted agents
    Altzerinakou, Maria
    Paoletti, Xavier
    TRIALS, 2017, 18
  • [29] Outcomes of Patients with Metastatic Melanoma Treated with Molecularly Targeted Agents in Phase I Clinical Trials
    Codesido, Montserrat Blanco
    Brunetto, Andre Tesainer
    Frentzas, Sophia
    Garcia, Victor Moreno
    Papadatos-Pastos, Dionysis
    Pedersen, Joanna Vitfell
    Trani, Leonardo
    Puglisi, Martina
    Molife, L. Rhoda
    Banerji, Udai
    ONCOLOGY, 2011, 81 (02) : 135 - 140
  • [30] Clinical benefit in phase I trials of novel molecularly targeted agents: Does dose matter?
    Postel-Vinay, S. C.
    Arkenau, H.
    Ashley, S.
    Barriuso, J.
    Olmos, D.
    Shaw, H.
    Wright, M.
    Judson, I.
    De-Bono, J.
    Kaye, S. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345